



RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 31st July 2019 – Following the press release issued yesterday, please be informed that the Independent Auditors' Report on the Condensed Interim Consolidated Financial Statements as at and for the six months ended 30 June 2019 is available to the public, as of today, at the Company's registered office, on the Company's website (www.recordati.com) and on the "1info" storage mechanism (www.linfo.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2018 was € 1,352.2 million, operating income was € 442.2 million and net income was € 312.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393

e-mail: investorelations@recordati.it

Media Relations
Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.